Company / PP&E (Net)
Sarepta Therapeutics PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$345.1M
FY2025
5-year range
$180.0M / $345.1M
FY2021-FY2025
Trend
+1.4%
vs FY2024
Sector context
#25 of 193
Health Care
What the data says
Sarepta Therapeutics's pp&e (net) of $345M is higher than 87% of companies in the Health Care sector (FY2025). PP&E (Net) has increased for 3 consecutive years, from $180M in FY2022 to $345M in FY2025.
Based on SEC 10-K filings.
$345M in FY2025 with a 5-year CAGR of +12.6%. Top quartile in the Health Care sector.
Improved from $227M to $345M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +24.2%
- 5-Year CAGR
- +12.6%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 193This company $345.1M Sector average $777.6M
▼
-55.6% below sector average
Key checks
Key Insights
- Sarepta Therapeutics's pp&e (net) has grown for 3 consecutive years.
- 5-year CAGR of +12.6%, indicating consistent growth.
- In FY2025, pp&e (net) increased 1.4% year-over-year.
- Ranks #25 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $345.1M | +1.4% |
| FY2024 | $340.3M | +49.8% |
| FY2023 | $227.2M | +26.2% |
| FY2022 | $180.0M | -5.8% |
| FY2021 | $191.2M | +0.4% |
| FY2020 | $190.4M | +46.9% |
| FY2019 | $129.6M | +33.6% |
| FY2018 | $97.0M | +124.8% |
| FY2017 | $43.2M | +14.2% |
| FY2016 | $37.8M | +1.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026